Depressive Disorder, Treatment-Resistant Clinical Trial
Official title:
A Randomised Pragmatic Trial Comparing the Clinical and Cost Effectiveness of Lithium and Quetiapine Augmentation in Treatment Resistant Depression
LQD is a multicentre randomised clinical trial comparing the clinical and cost effectiveness of lithium versus quetiapine when used as add-on therapies to antidepressant medication for patients with treatment resistant depression. The Lithium versus Quetiapine in Depression (LQD) study will assess patients over 12 months to establish which (if any) treatment is more likely to improve TRD over a long duration of time. Professor Anthony Cleare is the Chief Investigator and recruitment began in November 2016.
This 12 month parallel group, multi-centre, patient randomised, pragmatic, open label trial is comparing the clinical and cost-effectiveness of the decision to prescribe lithium versus quetiapine add-on treatment to antidepressant medication. There will be two parallel groups: 1) Quetiapine add-on to existing antidepressant medication; 2) Lithium add-on to existing antidepressant medication. 276 patients will be randomised 1:1 at baseline to the decision to prescribe either lithium or quetiapine, and treatment will then be undertaken by clinicians on a real world basis. All patients, regardless of their treatment status, will be followed up in the trial for one year. This is a superiority design whereby we hypothesise that quetiapine will be superior to lithium in terms of time to treatment discontinuation and average symptom burden (QIDS-SR) over 12 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03851380 -
Improving Brain Stimulation Through Imaging
|
||
| Completed |
NCT04977674 -
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
|
Early Phase 1 | |
| Completed |
NCT03207282 -
Treatment Resistant Depression in America Latina
|
||
| Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
| Completed |
NCT02691520 -
Epidemiology of Treatment Resistant Depression in Taiwan
|
Phase 4 | |
| Active, not recruiting |
NCT04159012 -
NESBID: Neuro-Stimulation of the Brain in Depression
|
N/A | |
| Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
| Completed |
NCT04239651 -
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
|
N/A | |
| Completed |
NCT02493868 -
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
| Completed |
NCT04599855 -
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
|
Phase 4 | |
| Completed |
NCT03283670 -
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
|
Phase 2 | |
| Recruiting |
NCT04783103 -
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
|
N/A | |
| Completed |
NCT03434041 -
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
| Terminated |
NCT03887624 -
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
|
Early Phase 1 | |
| Completed |
NCT02577250 -
Ketamine Infusions for PTSD and Treatment-Resistant Depression
|
Phase 1 | |
| Recruiting |
NCT02610712 -
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
|
Phase 4 | |
| Completed |
NCT03051256 -
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
|
Phase 2 | |
| Enrolling by invitation |
NCT05581797 -
Psilocybin-assisted Interpersonal Therapy for Depression
|
N/A | |
| Completed |
NCT02782104 -
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
|
Phase 3 | |
| Completed |
NCT04216888 -
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
|
Phase 2/Phase 3 |